Obesity
Conference Coverage
Triple-agonist retatrutide hits new weight loss highs
“I have never seen weight loss at this level” after nearly 1 year of treatment.
Conference Coverage
OASIS and PIONEER PLUS support high-dose oral semaglutide
OASIS-1 showed that “oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer...
Conference Coverage
SURMOUNT-2: Tirzepatide rings up major weight loss in type 2 diabetes
Taken together, results from SURMOUNT-1 and SURMOUNT-2 appear to make a good case for a weight-loss indication that will not depend on whether a...
News
NAFLD increases risk for severe infections
Physicians should assess their patients’ vaccination status and seek to control modifiable risk factors, such as diabetes.
Conference Coverage
BMI ‘vastly underestimates’ true obesity
“We’re at the start of the end of BMI.”
News
Insurers poised to crack down on off-label Ozempic prescriptions
Insurance companies are pushing back because many do not cover weight loss medications, while they do cover diabetes treatments.
News
Popular weight loss drugs can carry some unpleasant side effects
Specialists say starting with low doses and gradually increasing over time helps avoid side effects, but insurance companies often require a...
News
WHO advises against nonsugar sweeteners for weight control
“Replacing free sugars with NSS does not help with weight control in the long term. People need to consider other ways to reduce free sugars...
Commentary
Does weight loss surgery up the risk for bone fractures?
It’s important for people undergoing weight loss surgery to be cognizant of this potentially negative outcome and to take appropriate precautions...
News from the FDA/CDC
FDA warns people to avoid compounded semaglutide medicines
“Patients should be aware that some products sold as ‘semaglutide’ may not contain the same active ingredient as FDA-approved semaglutide products...